Breaking Finance News

A statement released earlier today by RBC Capital about ObsEva (NASDAQ:OBSV) bumps the target price to $22.00

Just yesterday ObsEva (NASDAQ:OBSV) traded 0.36% higher at $7.05. ObsEva’s 50-day moving average is $6.96 and its 200-day moving average is $10.41. The last stock price is down -32.72% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 4,982 shares of OBSV traded hands, down from an average trading volume of 11,875

RBC Capital raised the target price of ObsEva (NASDAQ:OBSV) to $22.00 reporting a possible upside of 2.12%.

Previously on 6/29/2017, HC Wainwright released a statement about ObsEva (NASDAQ:OBSV) increased the target price from $0.00 to $27.00. At the time, this indicated a possible upside of 3.58%.

Recent Performance Chart


ObsEva has with a one year low of $6.77 and a one year high of $14.18 and has a total market value of $0.

More About ObsEva (NASDAQ:OBSV)

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women's reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.